Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route
Autoantigen treatment has been tried for the prevention of type 1 diabetes (T1D) and to preserve residual beta-cell function in patients with a recent onset of the disease. In experimental animal models, efficacy was good, but was insufficient in human subjects. Besides the possible minor efficacy o...
Main Author: | Johnny Ludvigsson |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/5/1598 |
Similar Items
-
Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients
by: Rosaura Casas, et al.
Published: (2020-10-01) -
Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases
by: Ganesan Vinitha, et al.
Published: (2016-05-01) -
Identification of Novel Native Autoantigens in Rheumatoid Arthritis
by: Thomas B. G. Poulsen, et al.
Published: (2020-05-01) -
T-Zellrezeptorbindung und Modulation der T-Zellaktivierung durch Autoantigene der Ratte
by: Kreiß, Matthias
Published: (2004) -
An Epigenetics-Based Hypothesis of Autoantigen Development in Systemic Lupus Erythematosus
by: Wesley Brooks
Published: (2020-04-01)